Glioblastoma (GBM) is a particularly devastating tumor with a median survival of about 16
months. Recent research has revealed novel insights into the outstanding heterogeneity of …

Glioblastoma (GB) stands out as the most prevalent and lethal form of brain cancer.
Although great efforts have been made by clinicians and researchers, no significant …

The poor response of glioblastoma to current treatment protocols is a consequence of its
intrinsic drug resistance. Resistance to chemotherapy is primarily associated with …

The ubiquitin hydrolase OTUB1 has been elucidated to be highly expressed in tumors,
however, its roles in glioma progression are still confusing. Here, via analyzing several …

Background Laser interstitial thermal therapy (LITT) is a novel, minimally invasive alternative
to craniotomy, and as with any new technology, comes with a learning curve. Objective We …

Purpose Constructed from a theoretical framework, the coordinated undermining of survival
paths in glioblastoma (GBM) is a combination of nine drugs approved for non-oncological …

Glioblastoma multiforme (GBM) is the most common malignant primary brain tumor, known
for its poor prognosis and high recurrence rate. Current standard of care includes surgical …

Simple Summary Paediatric cancer research in general and neuroblastoma, in particular,
has minimal preclinical models of metastasis. As 50% of primary neuroblastomas have …

Glioblastoma (GBM) is a stage IV astrocytoma that carries a dismal survival rate of≈ 10
months postdiagnosis and treatment. The highly invasive capacity of GBM and its ability to …

Low‐grade gliomas (LGGs) are grade III gliomas based on the WHO classification with
significant genetic heterogeneity and clinical properties. Traditional histological …